Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy With Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Cetuximab sarotalocan (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Rakuten Medical
Most Recent Events
- 16 Aug 2024 Planned End Date changed from 31 Mar 2027 to 30 Jun 2026.
- 16 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2024 Planned End Date changed from 18 Sep 2025 to 31 Mar 2027.